Search

Your search keyword '"Tonini G."' showing total 68 results

Search Constraints

Start Over You searched for: Author "Tonini G." Remove constraint Author: "Tonini G." Publication Type Electronic Resources Remove constraint Publication Type: Electronic Resources
68 results on '"Tonini G."'

Search Results

1. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

2. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

3. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

4. Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients

5. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

6. Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia

7. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

8. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study

9. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study

10. Correction to: Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study (Archives of Dermatological Research, (2022), 314, 6, (593-603), 10.1007/s00403-021-02243-w)

11. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

12. Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies

13. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer

14. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

15. Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study

16. Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives

17. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

18. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

19. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

20. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

21. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

22. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

23. Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia

26. Activity and safety of cetuximab plus modified folfoxiri followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer a randomized phase 2 clinical trial

27. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

28. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study

29. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation

30. Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance?

31. EAGLES study: First-line bevacizumab in combination with chemotherapy in elderly patients with advanced, metastatic, non-squamous non-small cell lung cancer

32. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation

33. Deregulation of Ion Channel and Transporter Encoding Genes in Pediatric Gliomas

34. Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

35. Russian tourism in Italy: Trends, seasonality, and outliers

36. From motivation to opinions and satisfaction: How Russian tourists evaluate Italy

37. Forecasting models for updating monthly time series: The case of Russian tourism in Italy

38. Russian Tourism in Italy: Features, Dynamics, and Opinions

39. Dalle motivazioni alla soddisfazione : come i turisti russi giudicano l'Italia

40. Trend e stagionalità delle presenze turistiche russe in Italia

41. Modelli di previsione per l'aggiornamento di serie mensili del turismo russo in Italia

42. Case 2 – Anomalous retinal detachment: a case report of infraorbital desmoid fibromatosis

44. Tourist exchange between Italy and Russia

46. Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study

47. Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study

48. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

49. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

50. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).

Catalog

Books, media, physical & digital resources